Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biokine Therapeutics Ltd.

Latest From Biokine Therapeutics Ltd.

BioLineRx's CXCR4 Antagonist: Promising For Stem Cell Mobilization And AML

Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.

Clinical Trials Cancer

BioLineRx acquires Biokine's CXCR4 antagonist but switches target to leukaemia

BioLineRx has met a recent goal of adding an oncology asset to its pipeline and continued to fulfil its stated mission of filling the gap between basic research and late-stage development - especially among its Israeli colleagues - by licensing the worldwide rights to Biokine Therapeutics' BKT-140, now known as BL-8040.

Gastrointestinal Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Biokine Therapeutics Ltd.
  • Senior Management
  • Amnon Peled, PhD, CEO & CSO
  • Contact Info
  • Biokine Therapeutics Ltd.
    Phone: (972) 8 9301015
    Weizmann Science Park, Bldg. 13A
    P.O. Box 2213 Rehovot , 76120